Study guide

11.4 Cholestatic Liver Disease: PBC and PSC

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

11.4 Cholestatic Liver Disease: PBC and PSC

Key Takeaways Explain This Topic AI

Primary biliary cholangitis is antimitochondrial antibody positive in about 95% of cases and is treated first line with ursodeoxycholic acid.

Primary sclerosing cholangitis shows beading of the intra- and extrahepatic ducts on MRCP imaging, is strongly associated with ulcerative colitis, and carries a high risk of cholangiocarcinoma.

Pruritus in cholestatic liver disease is treated first line with colestyramine, with rifampicin as second line.

Last updated: September 2026

Disorders of the biliary tree and pancreas frequently feature in the MRCP(UK) Part 1 examination. Candidates are expected to differentiate between autoimmune cholestatic hepatopathies, manage gallstone-related biliary emergencies, master the diagnostic and prognostic criteria of acute pancreatitis, and direct the investigation and enzyme replacement therapy of chronic pancreatic exocrine insufficiency.

  • 1. Cholestatic Liver Diseases
  • Primary Biliary Cholangitis (PBC)

Epidemiology & Associations: Striking female preponderance (~9:1); typical age of onset 40–60 years. Associated with autoimmune conditions including Sjögren's syndrome (~70%) , Hashimoto's thyroiditis, systemic sclerosis (CREST syndrome), and coeliac disease.

Immunopathogenesis: T-cell mediated autoimmune destruction of the cholangiocytes lining intrahepatic interlobular and septal bile ducts (small ducts <100 um diameter) . The extrahepatic biliary tree is completely spared. Progressive ductopenia leads to chronic cholestasis, accumulation of cytotoxic bile salts, portal inflammation, and biliary cirrhosis.

Clinical Features: Insidious onset. The two cardinal early symptoms are disabling fatigue and intractable pruritus (typically worse at night, prominent on palms and soles, and often preceding jaundice by several years). Physical signs include excoriations, xanthelasma / xanthomas (due to severe hypercholesterolaemia with high HDL), cutaneous hyperpigmentation, and late jaundice. Significant risk of osteoporosis / osteopenia (malabsorption of fat-soluble vitamin D and osteoblast suppression), mandating baseline bone mineral density (DEXA) scanning.

Diagnostic Hallmarks:

Biochemical Profile: Markedly elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) ; transaminases (AST/ALT) are normal or mildly elevated. Serum bilirubin rises late and signifies advanced ductopenia and poor prognosis.

Serology: Antimitochondrial Antibodies (AMA) are positive in >95% of patients (specificity >98%) . Specifically targeted against the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) . Markedly elevated serum immunoglobulin M (IgM) is classic.

Liver Biopsy: Rarely required if ALP is elevated and AMA is positive. Histopathology demonstrates florid duct lesions : chronic granulomatous inflammation destroying interlobular bile ducts, ductopenia, and bridging fibrosis.

Therapeutic Management:

First-Line Disease-Modifying Agent: Ursodeoxycholic acid (UDCA) (13–15 mg/kg/day orally). A hydrophilic tertiary bile acid that replaces toxic endogenous bile acids, stimulates bicarbonate secretion, and exerts anti-apoptotic effects. Halts histological progression, delays need for liver transplantation, and improves transplant-free survival.

Second-Line Agents: Obeticholic acid (farnesoid X receptor [FXR] agonist) or fibrates ( bezafibrate , PPAR-alpha agonist) for patients with incomplete biochemical response or intolerance to UDCA.

Pruritus Management: First-line is colestyramine (bile acid sequestrant; must be dosed 2–4 hours before or after UDCA to avoid binding the drug); second-line agents include rifampicin, oral naltrexone, and sertraline.

Primary Sclerosing Cholangitis (PSC)

Epidemiology & Associations: Male predominance (~2:1); typical age of onset 30–50 years. 70–80% of patients have underlying Inflammatory Bowel Disease, overwhelmingly Ulcerative Colitis (typically pancolitis with rectal sparing and backwash ileitis). Conversely, ~5% of patients with UC develop PSC.

Immunopathogenesis: Chronic idiopathic fibroinflammatory obliterative cholangiopathy affecting both intrahepatic and extrahepatic bile ducts (large and small ducts) . Characterized by periductal fibrosis, diffuse stricturing, and biliary cirrhosis.

Clinical Presentation: Often asymptomatic, detected via persistent ALP elevation during routine IBD monitoring. Symptomatic patients experience fatigue, intermittent fluctuating jaundice, pruritus, right upper quadrant ache, and recurrent episodes of acute ascending bacterial cholangitis.

Diagnostic Hallmarks:

Biochemical Profile: Cholestatic pattern (elevated ALP and GGT).

Serology: Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) positive in 60–80% (atypical nuclear pattern). Serum IgG4 should be measured to rule out IgG4-related sclerosing cholangitis , a steroid-responsive mimic.

Diagnostic Imaging of Choice: Magnetic Resonance Cholangiopancreatography (MRCP) . Demonstrates multifocal segment-like strictures and intervening saccular dilatations involving intra- and extrahepatic bile ducts—the classic "beaded" appearance (string of beads).

Liver Biopsy: Rarely necessary; characteristically reveals concentric periductal fibrosis ( "onion-skin" fibrosis ) causing complete luminal obliteration and fibrous cords.

Malignancy Risks & Surveillance Protocols:

Cholangiocarcinoma (CCA): Lifetime risk of 10–15% (~1.5% annual incidence). Manifests as rapid clinical decompensation, weight loss, worsening jaundice, or an acute "dominant stricture". Surveillance: annual MRCP and serum carbohydrate antigen 19-9 ( CA 19-9 ).

Colorectal Carcinoma (CRC): 4- to 5-fold higher risk than in UC alone, with high propensity for right-sided colonic neoplasia. Mandatory guideline rule: Annual surveillance colonoscopy with chromoendoscopy and targeted/random biopsies from the time of PSC diagnosis , regardless of whether bowel disease is quiescent.

Gallbladder carcinoma: Annual ultrasound; cholecystectomy indicated for any gallbladder polyp >8 mm.

Management: No medical therapy halts progression (UDCA does not improve survival). Endoscopic balloon dilatation (with or without temporary stenting) for dominant strictures. Orthotopic liver transplantation is the only curative option for decompensated disease (recurs in 20–25% of allografts).

  • Diagnostic Domain Primary Biliary Cholangitis (PBC) Primary Sclerosing Cholangitis (PSC)
  • Demographics Females (90%); Age 40–60 years Males (70%); Age 30–50 years

Associated Diseases Sjögren's syndrome (70%), Hashimoto's thyroiditis, Scleroderma (CREST) Ulcerative Colitis (70–80%) ; Crohn's colitis

Anatomical Ducts Involved Strictly intrahepatic interlobular & septal ducts (small ducts <100 um) Both intrahepatic and extrahepatic biliary tree (large and small ducts)

Diagnostic Autoantibodies Antimitochondrial Antibodies (AMA M2) >95% ; Elevated serum IgM p-ANCA positive (60–80%) ; Elevated serum IgG / IgG4

Diagnostic Imaging (MRCP) Normal extrahepatic biliary tree; non-dilated ducts Multifocal strictures with intervening dilatation: "beaded" appearance

Histopathological Hallmark Granulomatous interlobular duct destruction ( "florid duct lesion" ) Concentric periductal fibrosis ( "onion-skin" fibrosis )

Malignancy Complications Hepatocellular carcinoma in advanced cirrhosis Cholangiocarcinoma (10–15% lifetime risk) ; Colorectal cancer

Disease-Modifying Therapy Ursodeoxycholic acid (UDCA 13–15 mg/kg/day) ; Obeticholic acid No medical therapy improves survival; Endoscopic dilatation; Liver transplant